SCHEMBL3568449

SCHEMBL3568449

N#Cc1cnc2oc(-c3ccccc3)c(-c3ccccc3)c2c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 3/20 0.48
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 3/20 0.42
ALOX15 P16050 1/20 0.42
HPGD P15428 3/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
AURKA O14965 8/20 0.41
CHEK1 O14757 4/20 0.41
MAP2K1 Q02750 1/20 0.41
KDR P35968 2/20 0.40
JAK3 P52333 2/20 0.40
PLK4 O00444 1/20 0.40
CHUK O15111 1/20 0.40
ROCK2 O75116 1/20 0.40
CHEK2 O96017 1/20 0.40
INSR P06213 1/20 0.40
CDK1 P06493 1/20 0.40
CSF1R P07333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13461956 0.86 KDM4E (0.43) TNK2ALDH1A1HSD17B10HPGDKDR
SCHEMBL13462029 0.84 TNK2 (0.48) TNK2ALDH1A1HSD17B10ALOX15HPGD
SCHEMBL3562506 0.84 TNK2 (0.55) TNK2ALDH1A1HSD17B10ALOX15HPGD
SCHEMBL3561541 0.79 TNK2 (0.51) TNK2ALDH1A1HSD17B10HPGDTSHR
SCHEMBL3566457 0.78 LRRK2 (0.49) TNK2ALDH1A1HSD17B10HPGDAURKA
SCHEMBL13436258 0.76 TNK2 (0.48) TNK2ALDH1A1HSD17B10HPGDTSHR
SCHEMBL3564842 0.74 AURKA (0.48) TNK2AURKACHEK1MAP2K1KDR
SCHEMBL3563328 0.74 AURKA (0.51) TNK2ALDH1A1HSD17B10HPGDTSHR
SCHEMBL3568846 0.73 TNK2 (0.50) TNK2AURKACHEK1MAP2K1KDR
SCHEMBL3579856 0.72 CHEK1 (0.47) TNK2ALDH1A1HSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 TNK2 22/4885ALDH1A1 869/4885HSD17B10 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.